RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics Additionally. chimeric antigen receptor (CAR)-T cell therapy, a type of adoptive cell therapy that combines the antigen specificity of an antibody with the effector functions of a T cell, has emerged as a promising immunotherapeutic strategy to improve the survival rates of patients with TNBC. Unlike the remarkable clinical success of CAR-T cell therapies in hematologic cancers with Kymriah and Yescarta, the development of CAR-T cell therapies for solid tumors has been much slower and is associated with unique challenges, including a hostile tumor microenvironment (TME).
ONCY's oncolytic virus pelareorep has demonstrated that can overcome a hostile TME while also demonstrating a synergistic effect when combined with CAR-T therapy, as evidenced by the work of Dr. Richard Vile of the Mayo Clinic.
Furthermore, ONCY's pelareorep is able to be synergistically combined with immune checkpoint inhibitors and CAR-T therapy, which in turn could be subsequenty combined with antibody drug conjugates (ADC), PARP & CDK 4,6 inhibitors, and bispecifics for effective treatment of liquid and solid tumors.
Consequently, ONCY is demonstrating that pelareorep is able to be combined with multiple IO agents, adoptive cell therapies, and small molecules to potentially treat various multiple cancers with current unmet treatment needs.